References

The pathophysiology of IgA nephropathy

10.1681/asn.2011050464 · 2011 · External reference

New developments in the genetics, pathogenesis, and therapy of IgA nephropathy

10.1038/ki.2015.252 · 2015 · External reference

The mucosa-kidney axis in IgA nephropathy

10.1681/asn.v11122395 · 2016 · External reference

IgA nephropathy: core curriculum 2021

10.1053/j.ajkd.2021.01.024 · 2021 · External reference

Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials

10.1053/j.ajkd.2015.10.011 · 2016 · External reference

KDIGO 2021 clinical practice guideline for the management of glomerular diseases

10.1016/j.kint.2021.05.021 · 2021 · External reference

SGLT-2 inhibition in IgA nephropathy: the new standard of care

10.1016/j.kint.2021.04.002 · 2021 · External reference

Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial

10.1016/s0140-6736(17)30550-0 · 2017 · External reference

Why target the gut to treat IgA nephropathy

10.1016/j.ekir.2020.08.009 · 2020 · External reference

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

10.1016/j.kint.2022.09.017 · 2023 · External reference

Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial

10.1016/s0140-6736(23)01554-4 · 2023 · External reference

The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility

10.1038/ki.2009.168 · 2009 · External reference

Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group

10.1016/j.kint.2017.02.003 · 2017 · External reference

Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial

10.1001/jama.2017.9362 · 2017 · External reference

Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy

10.1016/j.kint.2016.09.029 · 2017 · External reference

Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression

10.1007/s40620-015-0227-8 · 2016 · External reference

Single-cell analysis of endothelial cell injury in IgA nephropathy

10.1002/iid3.70149 · 2025 · External reference

The prognostic value of the systemic immune inflammation index in patients with IgA nephropathy

10.1080/0886022x.2024.2381613 · 2024 · External reference

Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration

10.15690/vsp.v21i3.2426 · 2007 · External reference

Proteinuria reduction as a surrogate end point in trials of IgA nephropathy

10.2215/cjn.08600718 · 2019 · External reference

GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials

10.1681/asn.2019010007 · 2019 · External reference

Long-term outcomes in IgA nephropathy

10.2215/cjn.0000000000000135 · 2023 · External reference

High neutrophil-to-lymphocyte ratio is an independent risk factor for end stage renal diseases in IgA nephropathy

10.3389/fimmu.2021.700224 · 2021 · External reference

Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors

10.1002/(sici)1097-0258(19960229)15:4<361::aid-sim168>3.0.co;2-4 · 1996 · External reference

Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks

10.1002/sim.5958 · 2013 · External reference

Decision curve analysis: a novel method for evaluating prediction models

10.1177/0272989x06295361 · 2006 · External reference

Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study

10.1681/asn.2014070697 · 2015 · External reference

Empagliflozin in patients with chronic kidney disease

10.1093/med/9780199568741.003.0163 · 2023 · External reference

A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy

10.1016/j.kint.2021.03.033 · 2021 · External reference

IgA nephropathy

10.1093/ckj/sfag146 · 2023 · External reference